logo
The 3-Day Hormone Reset Diet: Balancing Your Health Naturally with Food and Lifestyle Changes

The 3-Day Hormone Reset Diet: Balancing Your Health Naturally with Food and Lifestyle Changes

There's no denying that modern life messes with our hormones. From stress to processed food to poor sleep, we're constantly navigating internal chaos that leaves us tired, bloated, moody — and often wondering, What happened to my energy?
Good news: there's a way to get back in sync. And it doesn't involve expensive detox kits, hormone injections, or giving up coffee. The secret lies in simple, thoughtful shifts in how you eat, sleep, move, and hydrate.
Enter the 3-Day Hormone Reset Diet, a gentle, whole-food-based plan designed to help your body recalibrate using science-backed strategies that nourish from the inside out.
Hormones are the chemical messengers that regulate your metabolism, mood, energy, and more. When they're off, even just slightly, it can impact everything from sleep quality to skin health to how easily you lose (or gain) weight.
Factors like poor nutrition, stress, and inconsistent sleep can throw your hormones out of balance. Eating enough protein, engaging in regular movement, and reducing sugar and refined carb intake are foundational to hormonal health. Hormones are deeply tied to what you eat and how you live.
The Institute for Functional Medicine highlights that nutrition influences hormone signaling, including insulin sensitivity and thyroid function — two key areas often affected by modern diet and lifestyle. Think of your food choices as gentle levers for your internal balance.
This plan, designed by Dr. Colleen Cutcliffe, co-founder and CEO of Pendulum Therapeutics, isn't about deprivation. It's about adding in vibrant, fiber-rich foods and practicing small, sustainable habits that bring your system back into alignment.
Breakfast: Avocado-berry smoothie (hello, healthy fats + antioxidants) Lunch: Colorful veggie salad with olive oil & lemon dressing Dinner: Roasted veggie and quinoa bowl Lifestyle focus: Early bedtime (aim for 8 hours of restful sleep)
Why it works: Avocados and olive oil contain the kind of fats your hormones love. Bright berries and greens pack antioxidants to help lower inflammation and stabilize blood sugar, key for cortisol control.
Breakfast: Overnight chia pudding with fresh berries Lunch: Leafy green wrap with hummus & veggies (fiber-rich and gut-friendly) Dinner: Stir-fry with kale, broccoli, and tofu in avocado oil Lifestyle focus: Gentle yoga or a mindful 20-minute walk
Why it works: Cruciferous veggies like kale and broccoli support estrogen metabolism. Chia seeds deliver omega-3s, which help regulate inflammation and hormone production. Plus, movement boosts endorphins and serotonin, a mood-balancing win.
Breakfast: Mixed berries with coconut yogurt (probiotics + antioxidants) Lunch: Lentil soup topped with pumpkin seeds (fiber + minerals) Dinner: Veggie curry with coconut milk and cauliflower rice Lifestyle focus: Hydration—herbal teas, lemon water, and plenty of H₂O
Why it works: Coconut yogurt offers gut-healing probiotics. Fiber from lentils and seeds fuels beneficial gut bacteria. A happy gut means better hormone signaling, per the National Institutes of Health.
Healthy fats (like avocado, olive oil, and nuts) are essential for making steroid hormones such as estrogen and progesterone. Fats are also said to help regulate hunger hormones like leptin and ghrelin.
Antioxidant-rich produce like berries, leafy greens, and root vegetables reduce oxidative stress, which disrupts hormone production. Eating the rainbow is more than a cute concept, it's a science-backed strategy for hormone harmony. 'From coloring your plate to minimizing ultra-processed foods... hydration and sleep are obvious but powerful ones,' says Dr. Cutcliffe. 'Fiber really is the closest thing we have to a superpower right now.'
Cortisol (the stress hormone) throws off insulin and estrogen when elevated long-term. Prioritizing 7–9 hours of quality sleep each night is one of the most hormone-healing moves you can make.
A gentle overnight fast (12–14 hours) helps rebalance insulin sensitivity and supports cellular repair. This type of intermittent fasting gives your gut (and your hormones) a much-needed break.
Prebiotic fibers (found in artichokes, garlic, flaxseeds, and leafy greens) feed your gut microbiota, key players in metabolizing estrogen, thyroid hormones, and cortisol. 'A diet high in fiber and polyphenols will ensure a diverse gut microbiome that is metabolically healthy,' Dr. Cutcliffe explains.
Exercise helps reduce cortisol and increases feel-good neurotransmitters like serotonin and dopamine. A brisk daily walk or slow flow yoga session isn't just good for your body, it's medicine for your mood.
Refined carbs and added sugars create spikes in insulin and inflammation, which disrupt hormone signaling. The Institute for Functional Medicine confirms that ultra-processed foods negatively influence estrogen, insulin, and thyroid hormones.
Your body uses water to flush out excess hormones and toxins. It also supports metabolic pathways and keeps your lymphatic system moving. Herbal teas, lemon water, and hydrating foods like cucumber and watermelon all help.
If you're hoping for a single superfood or supplement to fix everything, take a deep breath because the truth is more empowering than that. 'I wish I had a golden ticket to give you that would unlock everything immediately,' says Dr. Cutcliffe. 'But there are various fairly established methods that can help... and fiber is a big one. So many Americans aren't getting enough of it in their diet.'
You don't need a 30-day cleanse or a hormone panel to start supporting your body. You just need to begin — by adding more fiber, swapping in good fats, prioritizing sleep, and giving your body a break from the chemical chaos of ultra-processed foods.
Your hormones aren't broken; they're just responding to your environment. And the beauty of this plan is that it works with your body, not against it. By adding in the right foods, making time for rest, moving your body gently, and drinking water like it's your new favorite accessory, you can support balance from within.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Measles in Iowa: What parents, and the public, should know about the first case in nearly six years
Measles in Iowa: What parents, and the public, should know about the first case in nearly six years

Yahoo

timea day ago

  • Yahoo

Measles in Iowa: What parents, and the public, should know about the first case in nearly six years

DES MOINES, Iowa — The first confirmed case of measles in Iowa since 2019 was announced by the state's Department of Health and Human Services on May 23, 2025. However, specific details on the patient and potential exposure of additional residents have been limited. 'Through our thorough investigation, it was learned this individual had traveled outside of the state of Iowa,' said HHS's Director of Communications Alex Murphy via email to WHO 13's Katie Kaplan. 'A thorough investigation has been completed. Public health officials will be reaching out to identified contacts, and no widespread public exposure is anticipated.' While the initial release from HHS on the confirmed Iowa case stated the patient was an unvaccinated adult, Murphy added that any further information about the specifics of the case was 'protected from disclosure under Iowa Code 139A.3(3).' While it is unconfirmed which medical facility the patient was treated at, WHO 13 was able to view internal messages from Central Iowa medical networks that were sent to area medical professionals. One noted that the Central Iowa resident may have recently traveled to Mexico and Texas. HHS confirmed to WHO 13 that the patient traveled internationally, but did not specify where. The announcement about the highly contagious viral illness that is spread through the air when an infectious person coughs, sneezes, or breathes was made late in the workday on a Friday afternoon before the Memorial Day weekend. 'Measles is as scary as it sounds because it's so contagious,' said Dr. Daniel Pelzer, a Pediatrician with the Iowa Clinic. 'It is 10 to 12 times more contagious than a normal flu virus that spreads around every year. And for that reason, it's important for us to get ahead of that so that the unvaccinated or under-vaccinated in our community aren't at risk.' Pelzer said local physicians have been following the growing number of cases across the U.S. and have been preparing for a local case for months. He added that the case, which HHS said tested positive at the State Hygienic Laboratory, activated the plans that include vetting patients through their symptoms, limiting exposure to the public, and the potential use of hazmat, or PPE (Personal Protective Equipment) gear, for health providers. He said the first step the public should take if they believe they have the measles, or have been exposed to the illness, is to pick up the phone. Des Moines police release name of motorcyclist killed in crash 'For parents, if you think you have a case of measles in your house, or a known exposure, call us. Again, measles is so contagious that if it would arrive in our office, it would grind the entire clinic to a halt because of the density of airborne virus transmission,' he said. According to the HHS, about 1 in 10 people in the U. S. who get measles will be hospitalized, and 1 to 3 out of 1,000 children with measles will die even with good medical care. Measles was declared 'eliminated' from the United States in 2000, according to the CDC. This meant the absence of the continuous spread of disease was greater than 12 months. Most people who have been fully vaccinated against the illness do not need booster shots and are 'less susceptible' to contracting it, Pelzer said. However, he said he has watched as immunizations in local children have fallen in recent years, specifically since the Pandemic. 'Herd immunity, about 95%, is what we need to effectively, in communities, limit the spread of measles,' he said. 'In the last decade that I've been a pediatrician in this town, I've seen that rate decrease from 95%, which is our safe rate, down to closer to 90% by our best guesses.' Measles symptoms include a high fever, cough, and runny nose, followed by a red rash most often found on the face and arms. Tiny white bumps may also develop inside the mouth. The illness can lead to swelling of the brain and other complications. 'The best time to prevent measles is before an exposure occurs, and the best tool we have is getting the measles, mumps, and rubella (MMR) vaccine,' said Dr. Robert Kruse, State Medical Director, via a written statement provided by the HHS. 'Getting vaccinated not only protects you but also protects people in your community who can't get vaccinated, like infants too young to begin the series and those who are immunosuppressed.' If you think you have been exposed to a measles case and have symptoms, call your medical provider or nearest emergency room ahead of time and tell them that you have been exposed to measles and have symptoms before arriving. Measles symptoms begin to appear 7-to-21 days after exposure. As of June 5, nearly two weeks after the announcement of the case, the HHS told WHO 13 that there have been no other confirmed cases of measles in the state of Iowa. Iowa News: Measles in Iowa: What parents, and the public, should know about the first case in nearly six years WHO 13 Farm Report: Thursday, June 5 Motorcyclist killed after being hit by semi in Floyd County identified Forecast: Mild temps and tiny rain chances WHO 13 Farm Report: Wednesday, June 4 Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

Yahoo

time2 days ago

  • Yahoo

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, with select results simultaneously published in Nature Medicine. MEDSIR's DEMETHER clinical trial was mentioned during abstract discussion due to the relevance of its strategy. CHICAGO, June 04, 2025--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients," stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: "Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients." Read more about TUXEDO-3 here: SHOWCASING PROMISING COLLABORATIVE TRIALS AT ASCO MEDSIR's trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today's Discussion of LBA1008. DEMETHER's strategy is to optimize the sequence to increase patients' progression free survival (PFS) while improving their quality of life. The relevance of this mention highlighted the ability of MEDSIR for anticipating patients' needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind. ABOUT MEDSIR For further information: View source version on Contacts Media Sergio Aguilar Eduardo Martín Espallargas

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options
New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

Business Wire

time2 days ago

  • Business Wire

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

CHICAGO--(BUSINESS WIRE)--Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II study funded by Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, evaluates the efficacy and safety of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases and leptomeningeal disease, serious complications associated with advanced stages of the cancer. "This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease" - Dr. Matthias Preusser. Share The study was carried out to evaluate HER3-DXd in patients with metastatic breast cancer (mBC) and advanced non-small cell lung cancer (aNSCLC) with active brain metastases, and patients with leptomeningeal disease from solid tumors. This is an antibody-drug conjugate to target HER3, a protein receptor found on the surface of cancer cells in brain metastases. HER3-DXd is an investigational agent consisting of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC Technology payload causes tumor DNA damage, killing cancer cells within and surrounding the tumor microenvironment The study showed promising results, which were presented today in an oral session. Results from the leptomeningeal cohort have been simultaneously published in the renowned journal Nature Medicine due to its potential benefit in patients with a high unmet medical need. In patients with breast cancer and brain metastases, intracranial responses were observed across all breast cancer subtypes, including luminal, HER2-positive, and triple-negative. A NEW HOPE FOR DIFFICULT-TO-TREAT METASTASES 'This study represents a significant advancement in our understanding of how to treat brain metastases and leptomeningeal disease, and we are hopeful that our findings will pave the way for new, effective therapies for these patients,' stated Dr. Matthias Preusser, MD, Medical Oncologist and Head of the Clinical Division of Oncology, Medical University of Vienna and Principal Investigator of TUXEDO-3. Dr. Rupert Bartsch, MD, PhD, Consultant Hematology and Medical Oncology, Medical University of Vienna, added: 'Brain metastases and leptomeningeal disease represent severe complications in cancer, leading to increased morbidity and mortality, and HER3-DXd could be a promising therapeutic alternative for these patients.' MEDSIR's trial DEMETHER, an international, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive recurrent metastatic breast cancer patients, was mentioned during today's Discussion of LBA1008. DEMETHER's strategy is to optimize the sequence to increase patients' progression free survival (PFS) while improving their quality of life. The relevance of this mention highlighted the ability of MEDSIR for anticipating patients' needs and designing strategical trials to keep on pushing the barriers of clinical research. MEDSIR active presence at the ASCO Annual Meeting 2025 reinforces its leadership in excellence-driven oncology research and highlights its focus on addressing unmet needs in cancer treatment, with the aim of not leaving any patient left behind.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store